Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | GRM4 | Q14833 | 6/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | FABP4 | P15090 | 1/20 | 0.35 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12350998 | 0.91 | GRM4 (0.43) | KMT2AMEN1GRM4RAB9A | |
| SCHEMBL12351003 | 0.88 | SLC13A3 (0.43) | KMT2AMEN1MAPTSMN1; SMN2 | |
| SCHEMBL2359845 | 0.87 | MEN1 (0.47) | KMT2AMEN1MAPTNPSR1POLB | |
| SCHEMBL2360096 | 0.83 | EPHX2 (0.34) | KMT2AMEN1 | |
| SCHEMBL2360243 | 0.83 | EPHX1 (0.45) | KMT2AMEN1MAPTPOLBRAB9A | |
| SCHEMBL12351010 | 0.81 | KMT2A (0.42) | KMT2AMEN1MAPTPOLBSMN1; SMN2 | |
| SCHEMBL2359771 | 0.80 | LMNA (0.44) | KMT2AMEN1MAPTPOLBSMN1; SMN2 | |
| SCHEMBL12351017 | 0.80 | IDO1 (0.40) | MAPT | |
| SCHEMBL2358740 | 0.78 | EPHX2 (0.43) | KMT2AMEN1POLBSMN1; SMN2RAB9A | |
| SCHEMBL12351016 | 0.77 | KDR (0.52) | KMT2AMEN1GRM4MAPTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011094953-A1 | COMPOUNDS FOR THE TREATMENT AND PREVENTION OF INFLUENZA | F. HOFFMANN-LA ROCHE AG (CH) | 2011-08-11 | — | — | WO | disclosed |
| WO-2011095576-A1 | COMPOUNDS FOR THE TREATMENT AND PREVENTION OF INFLUENZA | F. HOFFMANN-LA ROCHE AG (CH) | 2011-08-11 | — | — | WO | disclosed |
| WO-2011095576-A1 | COMPOUNDS FOR THE TREATMENT AND PREVENTION OF INFLUENZA | F. HOFFMANN-LA ROCHE AG (CH) | 2011-08-11 | — | — | WO | disclosed |
| US-20110195979-A1 | COMPOUNDS FOR THE TREATMENT AND PREVENTION OF INFLUENZA | F. HOFFMANN-LA ROCHE AG (CH) | 2011-08-11 | — | — | US | disclosed |
| US-20110195979-A1 | COMPOUNDS FOR THE TREATMENT AND PREVENTION OF INFLUENZA | F. HOFFMANN-LA ROCHE AG (CH) | 2011-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195979-A1 | COMPOUNDS FOR THE TREATMENT AND PREVENTION OF INFLUENZA | NAT1, NHERF1, ADORA1 | KMT2A 2790/4885MEN1 1215/4885GRM4 3238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.